Skip to content

A clinical trial to study the safety of Hyfil in normal healthy volunteers

Phase IV study of Hyfil in normal healthy volunteers following single intradermal administration

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2010/091/001123
Enrollment
48
Registered
2010-09-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Nasolabial fold correction

Interventions

Intervention1: Hyfil 0.5 ml: Hyfil 0.5 ml Intervention2: Hyfil 1.0 ml: Hyfil 1.0 ml Control Intervention1: Nil: Nil

Sponsors

Dr Hemanth Nandigala Executive Director Comm
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female, at least 18 years of age; 2. Signs a written informed consent; 3. Understands and accepts the obligation not to receive any other procedures in the dorsum of the hands for 1 month; 4. Understands and accepts the obligation and is logistically able to be present for all scheduled follow-up visits.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Has had any dermal fillers or surgery in the dorsum of the hand; 3. Subjects with allergic reaction to the study product.

Design outcomes

Primary

MeasureTime frame
Changes in erythema, edema and pain from baseline to 24, 48, 72 hrs, 7th day and 30th day during post-therapy ? visual assessment by investigator.Timepoint: Baseline,24,48,72 hrs,7th day and 30th day.

Secondary

MeasureTime frame
Incidence of adverse events and local injection site reactions.Timepoint: Baseline,24,48,72 hrs,7th day and 30th day.

Countries

India

Contacts

Public ContactDr TC Raghuram

Director

tcraghuram@gmail.com04023800924

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026